DK1856045T3 - 1-eddikesyreindolderviater med PGD2-antagonisteffekt - Google Patents
1-eddikesyreindolderviater med PGD2-antagonisteffektInfo
- Publication number
- DK1856045T3 DK1856045T3 DK06726357T DK06726357T DK1856045T3 DK 1856045 T3 DK1856045 T3 DK 1856045T3 DK 06726357 T DK06726357 T DK 06726357T DK 06726357 T DK06726357 T DK 06726357T DK 1856045 T3 DK1856045 T3 DK 1856045T3
- Authority
- DK
- Denmark
- Prior art keywords
- acetic acid
- indole derivatives
- antagonist effect
- alkyl
- acid indole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0505048.9A GB0505048D0 (en) | 2005-03-11 | 2005-03-11 | Compounds with PGD antagonist activity |
| PCT/GB2006/000851 WO2006095183A1 (en) | 2005-03-11 | 2006-03-10 | 1-acetic acid-indole derivatives with pgd2 antagonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1856045T3 true DK1856045T3 (da) | 2010-01-04 |
Family
ID=34508918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06726357T DK1856045T3 (da) | 2005-03-11 | 2006-03-10 | 1-eddikesyreindolderviater med PGD2-antagonisteffekt |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8044088B2 (el) |
| EP (1) | EP1856045B1 (el) |
| JP (1) | JP2008532990A (el) |
| KR (1) | KR20070116633A (el) |
| CN (1) | CN101166721A (el) |
| AT (1) | ATE442356T1 (el) |
| AU (1) | AU2006221784A1 (el) |
| BR (1) | BRPI0608732A2 (el) |
| CA (1) | CA2601980A1 (el) |
| CY (1) | CY1109532T1 (el) |
| DE (1) | DE602006009080D1 (el) |
| DK (1) | DK1856045T3 (el) |
| ES (1) | ES2333161T3 (el) |
| GB (1) | GB0505048D0 (el) |
| HK (1) | HK1109628A1 (el) |
| HR (1) | HRP20090654T1 (el) |
| IL (1) | IL185844A0 (el) |
| MX (1) | MX2007011091A (el) |
| NO (1) | NO20074641L (el) |
| NZ (1) | NZ561747A (el) |
| PL (1) | PL1856045T3 (el) |
| PT (1) | PT1856045E (el) |
| RS (1) | RS51016B (el) |
| RU (1) | RU2007134456A (el) |
| SI (1) | SI1856045T1 (el) |
| WO (1) | WO2006095183A1 (el) |
| ZA (1) | ZA200708159B (el) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SI2037967T1 (sl) | 2006-06-16 | 2017-04-26 | The Trustees Of The University Of Pennsylvania | Antagonisti receptorja za prostaglandin d2 za zdravljenje androgene alopecije |
| RU2458918C2 (ru) | 2006-07-22 | 2012-08-20 | Оксаген Лимитед | Соединения, обладающие антагонистической активностью по отношению к crth2 |
| CN101500996B (zh) | 2006-08-07 | 2012-07-04 | 埃科特莱茵药品有限公司 | (3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物 |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| DK2229358T3 (da) * | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| RU2503672C2 (ru) | 2008-01-18 | 2014-01-10 | Оксаген Лимитед | Соединения, обладающие активностью антагонистов crth2 |
| WO2009093029A1 (en) * | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US8470594B2 (en) * | 2008-04-15 | 2013-06-25 | President And Fellows Of Harvard College | Methods for identifying agents that affect the survival of motor neurons |
| US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| MY152062A (en) * | 2009-02-24 | 2014-08-15 | Merck Sharp & Dohme | Indole derivatives as crth2 receptor antagonists |
| SI2558447T1 (sl) | 2010-03-22 | 2015-01-30 | Actelion Pharmaceuticals Ltd. | Derivati 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-karbazola in njihova uporaba kot modulatorji prostaglandinskega receptorja d2 |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| BR112013026283A8 (pt) | 2011-04-14 | 2018-01-30 | Actelion Pharmaceuticals Ltd | derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético e seu uso como moduladores do receptor d2 de prostaglandina |
| SI2781508T1 (sl) * | 2011-11-17 | 2019-03-29 | Kbp Biosciences Co., Ltd. | Zlite obročne spojine, ki vsebujejo dušik za uporabo kot antagonisti CRTH2 |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
| US9797903B2 (en) | 2012-10-24 | 2017-10-24 | Winthrop-University Hospital | Non-invasive biomarker to identify subject at risk of preterm delivery |
| KR102116978B1 (ko) | 2013-10-07 | 2020-05-29 | 삼성전자 주식회사 | 그래핀 소자 및 그 제조 방법 |
| GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| AR099767A1 (es) | 2014-03-17 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2 |
| GB201407807D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| EP4420734A2 (en) | 2015-02-13 | 2024-08-28 | Institut National de la Santé et de la Recherche Médicale | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| WO2017019858A1 (en) | 2015-07-30 | 2017-02-02 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 |
| US10351560B2 (en) | 2015-09-15 | 2019-07-16 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| EP3682250A4 (en) | 2017-09-13 | 2021-03-03 | Progenity, Inc. | PRECLAMPSY BIOMARKERS AND RELATED SYSTEMS AND PROCEDURES |
| CN109180691B (zh) * | 2018-08-24 | 2020-07-10 | 武汉大学 | 一种c3-芳香型吡咯并吲哚类生物碱及其合成方法 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN113425714B (zh) * | 2021-08-04 | 2022-04-26 | 华南师范大学 | 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用 |
| CN114870018A (zh) * | 2022-05-12 | 2022-08-09 | 江南大学 | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 |
| WO2024192765A1 (en) * | 2023-03-23 | 2024-09-26 | Brown University | First in class use of the crth2 antagonist in treating neuromyelitis optica spectrum disorder (nmosd) and relevant autoimmune cns disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| OA11622A (en) * | 1998-03-31 | 2004-09-16 | Inst For Pharm Discovery Inc | Substituted indolealkanoic acids. |
| AU2003231509A1 (en) * | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| GB0504150D0 (en) * | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| RU2458918C2 (ru) * | 2006-07-22 | 2012-08-20 | Оксаген Лимитед | Соединения, обладающие антагонистической активностью по отношению к crth2 |
| DK2229358T3 (da) | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
| US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| WO2009093029A1 (en) * | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| EP2265581A1 (en) * | 2008-01-22 | 2010-12-29 | Oxagen Limited | Compounds having crth2 antagonist activity |
-
2005
- 2005-03-11 GB GBGB0505048.9A patent/GB0505048D0/en not_active Ceased
-
2006
- 2006-03-10 SI SI200630491T patent/SI1856045T1/sl unknown
- 2006-03-10 AU AU2006221784A patent/AU2006221784A1/en not_active Withdrawn
- 2006-03-10 NZ NZ561747A patent/NZ561747A/xx not_active IP Right Cessation
- 2006-03-10 MX MX2007011091A patent/MX2007011091A/es active IP Right Grant
- 2006-03-10 PT PT06726357T patent/PT1856045E/pt unknown
- 2006-03-10 DE DE602006009080T patent/DE602006009080D1/de active Active
- 2006-03-10 CA CA002601980A patent/CA2601980A1/en not_active Abandoned
- 2006-03-10 US US11/908,401 patent/US8044088B2/en not_active Expired - Fee Related
- 2006-03-10 CN CNA2006800139287A patent/CN101166721A/zh active Pending
- 2006-03-10 RU RU2007134456/04A patent/RU2007134456A/ru not_active Application Discontinuation
- 2006-03-10 KR KR1020077023379A patent/KR20070116633A/ko not_active Application Discontinuation
- 2006-03-10 JP JP2008500270A patent/JP2008532990A/ja active Pending
- 2006-03-10 BR BRPI0608732A patent/BRPI0608732A2/pt not_active IP Right Cessation
- 2006-03-10 EP EP06726357A patent/EP1856045B1/en active Active
- 2006-03-10 AT AT06726357T patent/ATE442356T1/de active
- 2006-03-10 RS RSP-2009/0534A patent/RS51016B/sr unknown
- 2006-03-10 PL PL06726357T patent/PL1856045T3/pl unknown
- 2006-03-10 ES ES06726357T patent/ES2333161T3/es active Active
- 2006-03-10 WO PCT/GB2006/000851 patent/WO2006095183A1/en active Application Filing
- 2006-03-10 DK DK06726357T patent/DK1856045T3/da active
-
2007
- 2007-09-10 IL IL185844A patent/IL185844A0/en unknown
- 2007-09-12 NO NO20074641A patent/NO20074641L/no not_active Application Discontinuation
- 2007-09-21 ZA ZA200708159A patent/ZA200708159B/xx unknown
-
2008
- 2008-04-08 HK HK08103897.0A patent/HK1109628A1/xx not_active IP Right Cessation
-
2009
- 2009-12-08 CY CY20091101280T patent/CY1109532T1/el unknown
- 2009-12-09 HR HR20090654T patent/HRP20090654T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20090654T1 (hr) | 2010-01-31 |
| AU2006221784A1 (en) | 2006-09-14 |
| NZ561747A (en) | 2010-03-26 |
| ATE442356T1 (de) | 2009-09-15 |
| NO20074641L (no) | 2007-11-01 |
| JP2008532990A (ja) | 2008-08-21 |
| IL185844A0 (en) | 2008-01-06 |
| KR20070116633A (ko) | 2007-12-10 |
| RU2007134456A (ru) | 2009-04-20 |
| CY1109532T1 (el) | 2014-08-13 |
| EP1856045B1 (en) | 2009-09-09 |
| CN101166721A (zh) | 2008-04-23 |
| PL1856045T3 (pl) | 2010-02-26 |
| MX2007011091A (es) | 2007-11-22 |
| BRPI0608732A2 (pt) | 2016-11-08 |
| HK1109628A1 (en) | 2008-06-13 |
| CA2601980A1 (en) | 2006-09-14 |
| ES2333161T3 (es) | 2010-02-17 |
| RS51016B (sr) | 2010-10-31 |
| US20100330077A1 (en) | 2010-12-30 |
| ZA200708159B (en) | 2009-11-25 |
| SI1856045T1 (sl) | 2010-01-29 |
| GB0505048D0 (en) | 2005-04-20 |
| PT1856045E (pt) | 2009-12-09 |
| US8044088B2 (en) | 2011-10-25 |
| WO2006095183A1 (en) | 2006-09-14 |
| EP1856045A1 (en) | 2007-11-21 |
| DE602006009080D1 (de) | 2009-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1856045T3 (da) | 1-eddikesyreindolderviater med PGD2-antagonisteffekt | |
| PE20091005A1 (es) | N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas | |
| CY1115533T1 (el) | Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr | |
| GB0510584D0 (en) | Organic compounds | |
| TW200637550A (en) | Thiazole-4-carboxamide derivatives as mGluR5 antagonists | |
| HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| CY1108455T1 (el) | Νεος στεροειδης αγωνιστης δια fxr | |
| EA200601364A1 (ru) | Производные хинолина и их применение в качестве ингибиторов микобактерий | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
| NO20080738L (no) | Fremgangsmater for neurobeskyttelse | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| NO20090979L (no) | (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater | |
| NO20085269L (no) | 2-tioksantinderivater som fungerer som MPO-inhibitorer | |
| NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| AR076362A1 (es) | Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras. | |
| ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| ATE492534T1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| CY1112638T1 (el) | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| NO20071319L (no) | Fremgangsmate for fremstilling av isotiazolderivater. | |
| CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| RU2008129623A (ru) | Ингибиторы ccr9 активности | |
| NO20090332L (no) | 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler |